Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1987 28
1988 15
1989 52
1990 117
1991 401
1992 248
1993 357
1994 424
1995 424
1996 480
1997 486
1998 719
1999 597
2000 666
2001 785
2002 862
2003 964
2004 1037
2005 1225
2006 1111
2007 1032
2008 1091
2009 1133
2010 1149
2011 1200
2012 1194
2013 1194
2014 1200
2015 1182
2016 1201
2017 1211
2018 1222
2019 1223
2020 983
Text availability
Article attribute
Article type
Publication date

Search Results

25,129 results
Results by year
Filters applied: . Clear all
Page 1
Tacrolimus - Pharmacokinetic Considerations for Clinicians.
Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S. Schutte-Nutgen K, et al. Curr Drug Metab. 2018;19(4):342-350. doi: 10.2174/1389200219666180101104159. Curr Drug Metab. 2018. PMID: 29298646 Review.
BACKGROUND: The calcineurin inhibitor tacrolimus (Tac) is an integral part of the standard immunosuppressive regimen after renal transplantation (RTx). ...We therefore review current state of the art aspects of tacrolimus pharmacokinetics including genetics or diffe …
BACKGROUND: The calcineurin inhibitor tacrolimus (Tac) is an integral part of the standard immunosuppressive regimen after renal tran …
Clinical pharmacokinetics of tacrolimus.
Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Venkataramanan R, et al. Clin Pharmacokinet. 1995 Dec;29(6):404-30. doi: 10.2165/00003088-199529060-00003. Clin Pharmacokinet. 1995. PMID: 8787947 Review.
Currently, most of the pharmacokinetic data available for tacrolimus are based on an enzyme-linked immunosorbent assay method, which does not distinguish tacrolimus from its metabolites. ...Tacrolimus is extensively bound to red blood cells, with a mean blood …
Currently, most of the pharmacokinetic data available for tacrolimus are based on an enzyme-linked immunosorbent assay method, which …
Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation.
Yu M, Liu M, Zhang W, Ming Y. Yu M, et al. Curr Drug Metab. 2018;19(6):513-522. doi: 10.2174/1389200219666180129151948. Curr Drug Metab. 2018. PMID: 29380698 Free PMC article. Review.
BACKGROUND: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line immunosuppressant which consists of the footstone as immunosuppressive regimens in kidney transplantation. ...
BACKGROUND: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line immunosuppressant which consists of the foot …
An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization.
Jouve T, Noble J, Rostaing L, Malvezzi P. Jouve T, et al. Expert Opin Drug Saf. 2019 Apr;18(4):285-294. doi: 10.1080/14740338.2019.1599858. Epub 2019 Apr 1. Expert Opin Drug Saf. 2019. PMID: 30909754 Review.
Minimization of tacrolimus exposure, using appropriate companion drugs, leads to the best renal outcomes in the long term. Also, reducing tacrolimus exposure variability helps in reducing tacrolimus toxicity. ...In this review, the authors summarize the safet …
Minimization of tacrolimus exposure, using appropriate companion drugs, leads to the best renal outcomes in the long term. Also, redu …
Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients.
Pennington CA, Park JM. Pennington CA, et al. Am J Health Syst Pharm. 2015 Feb 15;72(4):277-84. doi: 10.2146/ajhp140322. Am J Health Syst Pharm. 2015. PMID: 25631834 Review.
PURPOSE: Available data regarding sublingual tacrolimus were analyzed to provide recommendations for solid organ transplant recipients. ...A review of the currently available literature revealed nine reports of sublingual tacrolimus use in human subjects. Seven repo …
PURPOSE: Available data regarding sublingual tacrolimus were analyzed to provide recommendations for solid organ transplant recipient …
Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations.
Tremblay S, Alloway RR. Tremblay S, et al. AAPS J. 2017 Sep;19(5):1332-1347. doi: 10.1208/s12248-017-0119-z. Epub 2017 Jul 17. AAPS J. 2017. PMID: 28717926 Review.
Clinical trials from early development of immediate release tacrolimus to formulation-specific post-marketing trials of modified release tacrolimus formulations are reviewed with an emphasis on key elements relating to trial design end endpoint assessment. ...In add …
Clinical trials from early development of immediate release tacrolimus to formulation-specific post-marketing trials of modified rele …
Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH, Shin HY, Kim SM. Kim YH, et al. Yonsei Med J. 2019 Jul;60(7):633-639. doi: 10.3349/ymj.2019.60.7.633. Yonsei Med J. 2019. PMID: 31250577 Free PMC article.
We investigated the long-term safety and efficacy of tacrolimus for the treatment of MG in real-world clinical practice. MATERIALS AND METHODS: We retrospectively reviewed 160 MG patients treated with tacrolimus from 2005 to 2015. ...Adverse events due to tacroli
We investigated the long-term safety and efficacy of tacrolimus for the treatment of MG in real-world clinical practice. MATERIALS AN …
Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis.
Huang X, Xu B. Huang X, et al. Dermatology. 2015;231(1):41-9. doi: 10.1159/000381948. Epub 2015 May 30. Dermatology. 2015. PMID: 26043855 Review.
No significance was found between tacrolimus and pimecrolimus in improving the severity of eczema. More patients tended to withdraw in the vehicle groups compared to the tacrolimus and pimecrolimus groups. No significant difference existed between total adverse even …
No significance was found between tacrolimus and pimecrolimus in improving the severity of eczema. More patients tended to withdraw i …
Position statement: topical calcineurin inhibitors in atopic dermatitis.
Remitz A, De Pità O, Mota A, Serra-Baldrich E, Vakirlis E, Kapp A. Remitz A, et al. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2074-2082. doi: 10.1111/jdv.15272. Epub 2018 Nov 6. J Eur Acad Dermatol Venereol. 2018. PMID: 30288799 Review.
Whilst topical calcineurin inhibitors (TCIs), tacrolimus ointment and pimecrolimus cream, have proven efficacy for the treatment of AD, it is important to involve experts to obtain their opinion on its optimal treatment. ...CONCLUSION: Topical calcineurin inhibitors are a …
Whilst topical calcineurin inhibitors (TCIs), tacrolimus ointment and pimecrolimus cream, have proven efficacy for the treatment of A …
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
Staatz CE, Tett SE. Staatz CE, et al. Clin Pharmacokinet. 2004;43(10):623-53. doi: 10.2165/00003088-200443100-00001. Clin Pharmacokinet. 2004. PMID: 15244495 Review.
Population analyses are adding to our understanding of the pharmacokinetics of tacrolimus, but such investigations are still in their infancy. ...Little is known about the magnitude of the pharmacodynamic variability of tacrolimus....
Population analyses are adding to our understanding of the pharmacokinetics of tacrolimus, but such investigations are still in their …
25,129 results
Jump to page
Feedback